Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Curr Med Chem. 2019;26(25):4786-4798. doi: 10.2174/0929867326666190228115423.
Preeclapmsia (PE) is characterized by early onset symptoms such as elevated blood pressure, proteinuria and edema in the pregnant woman, and may result in seizures in the affected female. Currently, there are no therapeutic drugs available to treat this condition, but there are interventions to regulate the symptoms based on the gestational period of the fetus, although the largely favored option is delivery of the fetus and placenta.
A search for biomolecules associated with PE was conducted so as to identify diagnostic markers and therapeutic leads.
The literature search resulted in the identification of biomolecules such as Corin and Placental Protein 13 (PP13), among others that are associated with PE. Thereby, giving an insight into the various mechanistic pathways involved in the causation of PE. However, it is also evident that PE cannot be solely attributed to any single mechanism but is due to an interplay of different factors that have led to the development of this disease condition.
The identified biomarkers would ultimately help in understanding this complex disease and perhaps lead to the discovery of potential effective molecular targets for clinical trials, thereby providing a valuable therapeutic option for affected pregnant women.
子痫前期（PE）的特征是孕妇出现高血压、蛋白尿和水肿等早期症状，并且可能导致受影响的女性发生抽搐。目前，尚无治疗该病的特效药物，但有一些干预措施可根据胎儿的妊娠周期来调节症状，尽管大多数人倾向的选择是分娩胎儿和胎盘。
寻找与子痫前期相关的生物分子，以确定诊断标志物和治疗靶点。
文献检索确定了与子痫前期相关的生物分子，如 Corin 和胎盘蛋白 13（PP13）等。这使我们深入了解了导致子痫前期发生的各种机制途径。然而，也很明显，子痫前期不能仅仅归因于任何单一机制，而是由于不同因素的相互作用导致了这种疾病的发生。
所确定的生物标志物最终将有助于理解这种复杂的疾病，并可能为临床试验发现潜在有效的分子靶点提供依据，从而为受影响的孕妇提供有价值的治疗选择。
